Key facts
- It has raised $9.0M across 1 recorded rounds; the latest was Seed Round ($4.1M) in May 2022.
- Notable investors include Bantam Group, Arkitekt Ventures, BroadOak Capital Partners, Civilization Ventures, Cystic Fibrosis Foundation — 7 tracked in total.
- Nanite has filed 1 Form D with the SEC, most recently May 2022 ($4.1M sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Nanite
Funding rounds
1 roundsAbout Nanite
Developer of programmable polymer nanoparticles intended for non-viral gene delivery. The company's artificial intelligence-driven platform combines cutting-edge high-throughput experimental and computational methods to design fit-for-purpose delivery vehicles delivering a broad range of genetic cargoes with tissue specificity, helping scientists in functional chemistry to design therapeutically relevant gene delivery vehicles.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2021
- Employees
- 23
- Website
- nanitebio.com/
- Ownership
- Privately Held (backing)
Nanite doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nanite shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nanite in its N-PORT filings yet. We sweep new filings monthly.